N-甲基-1-甲硫基-2-硝基乙烯胺 | 168127-08-0

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: N-甲基-1-甲硫基-2-硝基乙烯胺
• 英文名称: (Z)-N-methyl-1-methylthio-2-nitroethenamine
• 英文别名: N-methyl-1-methylthio-2-nitroethyleneamine；(Z)-N-methyl-1-(methylthio)-2-nitroethene-1-amine；(Z) N-methyl-1-(methylthio)-2-nitroethenamine；(Z)-N-methyl-1-(methylthio)-2-nitroethenamine；2-methylamino-2-methylthio-1-nitroethene；N-(1-methylthio-2-nitrovinyl)-N-methylamine；N-Methyl-1-(methylthio)-2-nitroethenamine, (Z)-；(Z)-N-methyl-1-methylsulfanyl-2-nitroethenamine
• CAS: 168127-08-0
• 化学式: C₄H₈N₂O₂S
• 分子量: 148.186
• InChiKey: YQFHPXZGXNYYLD-ARJAWSKDSA-N

物化性质

• 沸点：
  236.5±35.0 °C(Predicted)
• 密度：
  1.199±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  83.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-甲基-1-甲硫基-2-硝基乙烯胺 在 聚合甲醛 、 甲胺 作用下， 以 乙醇 为溶剂， 生成 1,3-dimethyl-4-methylthio-5-nitro-1,2,3,6-tetrahydropyrimidine
  参考文献：
  名称：

  Nitro-substituted heterocyclic compounds

  摘要：

  公式为 ##STR1## 的杀虫亚硝基取代的杂环化合物，其中 R.sup.1 代表氢、氰或 C.sub.1-4 烷基，m 代表 0 或 1，n 代表 0 或 1，R.sup.2 代表氢或 C.sub.1-4 烷基，R.sup.3 代表氢、C.sub.1-6 烷基（可以选择性地被氰、卤素或 C.sub.1-4 烷氧基取代）、C.sub.3-4 烯基、C.sub.3-4 炔基、可以选择性地被取代的苯基、可以选择性地被取代的苄基或可以选择性地被取代的杂环甲基，T 代表可以选择性地被取代的含杂原子和/或碳原子的二元或三元链，A 代表可以选择性地被取代的苯基或至少包含 N、O 和 S 中的一种杂原子的可以选择性地被取代的五元或六元杂环基。

  公开号：

  US05081132A1
• 作为产物：
  描述：

  methyl carbonimidodithioic acid dimethyl ester 以 硝基甲烷 、 苯 为溶剂， 生成 N-甲基-1-甲硫基-2-硝基乙烯胺
  参考文献：
  名称：

  Improved process for the preparation of 1-substituted

  摘要：

  本发明揭示了一种制备通式为(R1NH)(R2S)C.dbd.CR3(NO2)的1-取代氨基-1-取代硫-2-硝基烯的方法，其中R1、R2、R3可以相同也可以不同，可以包括氢、烷基、芳基或芳基烷基或它们的组合。这些烯烃是通过在一种初级催化剂的存在下，将一种初级胺与硫化合物反应制备得到一种碳亚氨基二硫酸盐，然后将其转化为相应的酯，随后在一种次级催化剂的存在下与硝基化合物发生反应制备而得。1-甲基氨基-1-甲基硫-2-硝基乙烯是在合成雷尼替丁和尼扎替丁时的重要中间体，它们被用作治疗消化性溃疡和相关胃肠道疾病的有效药物。

  公开号：

  US04967007A1

文献信息

• Haloguanidine compounds, pharmaceutical compositions and methods of use
  申请人：ICI Americas Inc.

  公开号：US04362728A1

  公开（公告）日：1982-12-07

  Compounds useful for inhibiting gastric acid secretion and for the treatment of peptic ulcers caused or exacerbated by gastric acidity having the following formula (I): ##STR1## in which R.sup.1 and R.sup.2, are H, C.sub.1-10 alkyl, C.sub.3-8 cycloalkyl or cycloalkylalkyl in which the alkyl part is C.sub.1-6 and the cycloalkyl part is C.sub.3-8, each of the alkyl, cycloalkyl and cycloalkylalkyls being optionally substituted by one or more halogens selected from F, Cl and Br, provided that at least one of R.sup.1 and R.sup.2 is a halogen substituted alkyl, cycloalkyl or cycloalkylalkyl and provided that there is no halogen substituent on the carbon directly attached to the nitrogen; and X, m, Y, n and R.sup.3 are as described in the specification; and the pharmaceutically-acceptable acid-addition salts thereof. Processes for producing compounds of formula (I), pharmaceutical compositions containing them, methods of utilizing such compositions and intermediates useful for synthesizing compounds of formula (I) are also described.

  用于抑制胃酸分泌和治疗由胃酸引起或加重的消化性溃疡的化合物具有以下结构式（I）：##STR1##其中R.sup.1和R.sup.2为H，C.sub.1-10烷基，C.sub.3-8环烷基或环烷基烷基，其中烷基部分为C.sub.1-6，环烷基部分为C.sub.3-8，每个烷基，环烷基和环烷基烷基可选择地被来自F、Cl和Br的一个或多个卤素取代，前提是R.sup.1和R.sup.2中至少有一个是卤素取代的烷基，环烷基或环烷基烷基，并且直接连接到氮的碳上没有卤素取代物；X，m，Y，n和R.sup.3如规范中所述；以及其药用可接受的酸加盐。还描述了制备结构式（I）化合物的方法，含有它们的药物组合物，利用这种组合物的方法以及用于合成结构式（I）化合物的中间体。
• Aminoalkyl furan derivatives
  申请人：Allen & Hanburys Limited

  公开号：US04128658A1

  公开（公告）日：1978-12-05

  Compounds of the general formula I: ##STR1## and physiologically acceptable salts thereof and N-oxides and hydrates, in which R.sub.1 and R.sub.2 which may be the same or different represent hydrogen, lower alkyl, cycloalkyl, lower alkenyl, aralkyl or lower alkyl interrupted by an oxygen atom or a group ##STR2## in which R.sub.4 represents hydrogen or lower alkyl or R.sub.1 and R.sub.2 may, together with the nitrogen atom to which they are attached, form a heterocyclic ring which may contain other heteroatoms selected from O and ##STR3## R.sub.3 is hydrogen, lower alkyl, lower alkenyl or alkoxyalkyl; X is --CH.sub.2 --, O or S; Y represents .dbd. S, .dbd. O, .dbd. NR.sub.5 or .dbd. CHR.sub.6 ; Alk denotes a straight or branched alkylene chain of 1 to 6 carbon atoms; R.sub.5 is H, nitro, cyano, lower alkyl, aryl, alkylsulphonyl, or arylsulphonyl; R.sub.6 represents nitro, arylsulphonyl or alkylsulphonyl; M is an integer from 2 to 4; and N is 1 or 2; or when X .dbd. S, or --CH.sub.2 --, n is zero, 1 or 2. These compounds have H.sub.2 -antagonist activity. Intermediates in the production thereof are also provided.

  通式I的化合物：##STR1##及其生理上可接受的盐和N-氧化物和水合物，其中R.sub.1和R.sub.2可以相同也可以不同，代表氢、较低的烷基、环烷基、较低的烯基、芳基烷基或被氧原子或基团##STR2##中断的较低烷基，其中R.sub.4代表氢或较低烷基或R.sub.1和R.sub.2可以与它们连接的氮原子一起形成可能包含其他杂原子O和##STR3##的杂环环，R.sub.3是氢、较低烷基、较低烯基或烷氧基烷基；X是--CH.sub.2--、O或S；Y代表.dbd. S、.dbd. O、.dbd. NR.sub.5或.dbd. CHR.sub.6；Alk表示由1到6个碳原子的直链或支链烷基链；R.sub.5是H、硝基、氰基、较低烷基、芳基、烷基磺酰基或芳基磺酰基；R.sub.6代表硝基、芳基磺酰基或烷基磺酰基；M是从2到4的整数；N是1或2；或当X.dbd.S或--CH.sub.2--时，n为零、1或2。这些化合物具有H.sub.2-拮抗活性。还提供了其生产中间体。
• Benzopiperidine derivatives
  申请人：Eisai Co., Ltd.

  公开号：US06518423B1

  公开（公告）日：2003-02-11

  Benzopiperidine derivatives represented by formula (I), salts thereof or hydrates thereof, processes for producing the same and drugs comprising the same: wherein the variables are as described in the specification. These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and rejection reaction accompanying organ transplantation.

  本茨哌啶衍生物，由公式(I)表示，其盐或水合物，其制备方法以及包含其的药物: 其中变量如说明书中所述。这些化合物作为药物有效，用于预防和治疗这些各种炎症性疾病和免疫性疾病，如类风湿性关节炎、特应性皮炎、银屑病、哮喘和伴随器官移植的排斥反应。
• Catalyst-free synthesis of thiazolidines <i>via</i> sequential hydrolysis/rearrangement reactions of 5-arylidenethiazolidin-4-ones at room temperature
  作者：Fanxun Zeng、Letian Zhang、Xusheng Shao、Zhong Li、Xiaoyong Xu

  DOI：10.1039/c7ob02924a

  日期：——

  A catalyst-free sequential reaction involving hydrolysis and intramolecular aza-Michael addition was developed for synthesizing functionalized thiazolidines from 5-arylidenethiazolidin-4-ones at room temperature. A series of thiazolidine-5-carboxylic acids were prepared in good to excellent yields (up to 97% yield) and excellent diastereoselectivities (up to >20 : 1 dr). This methodology was applicable

  开发了涉及水解和分子内氮杂-Michael加成反应的无催化剂顺序反应，用于在室温下从5-芳基吡喃唑啉-4-酮合成官能化的噻唑烷。制备了一系列噻唑烷-5-羧酸，具有良好至优异的产率（高达97％的产率）和优异的非对映选择性（高达> 20：1 dr）。该方法可用于构建噻虫啉和氟噻吩的高收率衍生物。
• Synthesis of Novel Functionalized Derivatives of 5-Nitro-3,4-dihydropyrimidin-2(1<i>H</i>)-one by the Cyclocondensation of 1-Chlorobenzyl Isocyanates with <i>N</i>,<i>S</i>- and <i>N</i>,<i>N</i>-Nitroketeneacetals
  作者：Mykhaylo Vovk、Volodymyr Sukach、Andriy Bol’but、Alexander Petin

  DOI：10.1055/s-2007-965933

  日期：2007.3

  The cyclocondensation of 1-chlorobenzyl isocyanates with S,N- and N,N-nitroketeneacetals has been employed to synthesize hitherto-unknown 6-methylthio-5-nitro-3,4-dihydropyrimidin-2(1H)-ones, 8-nitro-2,3,6,7-tetrahydroimidazo[1,2-c]pyrimidin-5(1H)-ones and 9-nitro-1,2,3,4,7,8-hexahydro-6H-pyrimido[1,6-a]pyrimidin-6(1H)-ones. Substitution of the methylthio group in 6-methylthio-5-nitro-3,4-dihydropyrimidin-2(1H)-ones provided 6-amino-5-nitro-3,4-dihydropyrimidin-2(1H)-ones, which exist in tautomeric equilibrium with 4-imino-5-nitro-3,4,5,6-tetrahydropyrimidin-2(1H)-ones. The compounds obtained, if boiled in dioxane in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), eliminate the nitro groups to give substituted 4-imino-3,4-dihydropyrimidin-2(1H)-ones.

  1-氯苄异氰酸酯与S,N-和N,N-硝基烯酰基的环缩合反应被用来合成迄今为止未知的6-硫甲基-5-硝基-3,4-二氢嘧啶-2(1H)-酮、8-硝基-2,3,6,7-四氢咪唑[1,2-c]嘧啶-5(1H)-酮以及9-硝基-1,2,3,4,7,8-六氢-6H-吡咯[1,6-a]嘧啶-6(1H)-酮。对6-硫甲基-5-硝基-3,4-二氢嘧啶-2(1H)-酮中硫甲基的取代生成6-氨基-5-硝基-3,4-二氢嘧啶-2(1H)-酮，该化合物与4-亚氨基-5-硝基-3,4,5,6-四氢嘧啶-2(1H)-酮存在互变异构平衡。如果将所获得的化合物在1,8-二氮双环[5.4.0]十一烯（DBU）存在下于二噁烷中加热，会消除硝基生成取代的4-亚氨基-3,4-二氢嘧啶-2(1H)-酮。